POROS XS: A Next-Generation Cation Exchange Chromatography Resin

A High-Resolution, High-Capacity Salt Tolerant Solution for Bioseparations

No sessions of this seminar are currently scheduled. If you are interested in attending future sessions of this seminar, please contact Tony Chenhansa at bp@lifetech.com

Would you like to learn about a new chromatography resin that could revolutionize your approach to capture and polish chromatography?

Learn from the experts about how the Applied Biosystems® POROS®XS resin is ideal for process-scale bioseparations. This breakthrough resin combines optimal particle size, pore size and surface chemistry to provide superior process peformance.

Now you can have a resin with with both high capacity (100mg/ml) and high resolution for the purification of Monoclonal antibodies.

Participants will learn:

  • The current downstream demands of the biopharma industry.
  • How the performance of POROS® XS provides high capacity, superior resolution, and unparalleled salt tolerance.
  • The design space for optimal dynamic binding capacity
  • How superior capacity can be obtained over a broad range of process conditions.
  • How POROS® XS provides improved yield and throughput with added process flexibility.

When: Tuesday, September 14, 2010

  • 10:00 a.m.(EST)/3:00 p.m.(GMT)
  • 12:30 p.m.(PST)/3:30 p.m.(EST)

(Can’t make the date? Sign up, and we’ll send you the link to the recording.)

Ask the Expert! Live Q&A will follow the short presentation.

Cost: Enrollment in the course is free.

About the Presenters
Christine Gebski, M.S.
Christine Gebski, M.S., Director, R&D and Field Applications, Life Technologies

Ms. Gebski is currently the Director of the Process Chromatography R&D and Field Applications groups in the Bioproduction Division of Life Technologies. The R&D group is responsible for new product development, manufacturing technical support, and the development of POROS® XS. The Field Applications group provides worldwide support to POROS® process bulk and analytical customers and sales teams. Prior to joining Life Technologies, Ms. Gebski worked at Genzyme, Transkaryotic Therapies (TKT, now Shire) and EMD Pharmaceuticals as a Process Development Scientist for 15 years. She is experienced in both development and engineering and had responsibility for developing, scaling, transferring and validating downstream purification processes. Ms. Gebski developed unit operations from clarification through lyophilization, with an emphasis on chromatography and filtration. She has also developed purification processes for products in pre-clinical through commercial phases, including plasma derived proteins, monoclonal antibodies and other recombinant proteins.

Ms. Gebski has a B.S. in Biology from the University of Vermont and a M.S. in Biotechnology from the University of Massachusetts at Lowell.


Webinars by MeetingBridge